usdaed

The numbers? Let’s not get bogged down in boring details, but just to indulge you… MercadoLibre, DLocal, and Nu grew revenue by 45%, 65%, and 57% respectively, last quarter. Meanwhile, some of the US giants we’re all supposed to worship? A measly 4%. It’s almost…rude. And the best part? They’re all currently having a bit of a wobble, trading well off their highs. A wobble, my friends, is an opportunity. So, let’s head south and see what all the fuss is about, shall we?

Nvidia, designated as NVDA, presents itself as a leading provider of graphical processing units, a component essential to the acceleration of data. It is a cog, a precisely engineered piece within a larger, incomprehensible machine. The stock, for the past eight months, has maintained a curious stillness, a bureaucratic inertia that defies the relentless reporting of “stellar results.” One is reminded of a file, meticulously documented, yet perpetually lost within the archives.

France, it is observed, generates seventy percent of its electricity from these silent, contained fires, a testament to a long-held commitment. And now, even Japan, chastened by past misfortune yet ever mindful of its resource scarcity, stirs from its slumber, seeking to reclaim twenty percent of its power generation from the atom. South Korea, with its characteristic diligence, lays plans for reactors vast and new, envisioning a future powered by controlled fission. Here, in America, the Department of Energy speaks of tripling nuclear capacity, a goal ambitious, perhaps, but reflective of a growing realization that dependence on fuels of the past is a path to eventual impoverishment.

The fine print says it’s based on a weighted average purchase price of $13.78. $13.78! Who even uses decimal places like that for stock prices? It feels…artificial. And then they calculate the post-transaction value based on the market close on March 12th. March 12th! As if the market is some sort of static entity. It’s constantly shifting. It’s…it’s a moving target! They’re just picking a date to make the numbers look…neat.

But here’s the thing. Wall Street insiders – those people who, theoretically, know what they’re doing – haven’t entirely given up on it. There’s been some insider buying recently, a rather significant investment from General Atlantic, its biggest institutional shareholder. Which is…interesting. It’s like seeing your ex suddenly start leaving thoughtful gifts on your doorstep. You’re not entirely sure what they’re up to, but it’s definitely a signal.

It has come to pass that the U.S. Department of Defense, a body not known for its impulsive decisions, has bestowed upon Palantir a most significant endorsement. This is no mere contract, mind you, but a formal declaration – a “program of record,” as they say – solidifying the company’s position as a trusted advisor in matters of national security. A curious turn of events, wouldn’t you agree?

Abbott Laboratories (ABT) presents a compelling case for inclusion in a defensive portfolio due to its diversified revenue streams and established track record of shareholder returns. The company operates across four primary segments – medical devices, diagnostics, nutrition, and established pharmaceuticals – mitigating idiosyncratic risk associated with any single business line. This diversification proved particularly advantageous during the pandemic, with diagnostic revenue offsetting potential weakness in other areas. Currently, the medical device segment is driving growth, suggesting adaptability and resilience.

The weighted average price, as dutifully recorded by the SEC Form 4, came to $32.67. A price, one imagines, that will scarcely be remembered by the end of the fiscal year.

Diamondback, a name that evokes a certain resilience, is rooted in the Permian Basin – that vast, sun-drenched expanse of West Texas and New Mexico where the earth yields its dark treasure. It is a company that does not shout its ambitions, but rather, cultivates them with a deliberate, almost pastoral care. They are not gamblers chasing fleeting fortunes, but stewards of a resource, mindful of both its bounty and its limits.

And where does one presently locate this potential brilliance? Within the polished, almost unnervingly reflective realm of technology, specifically, the fabrication of semiconductors. A sector that, while enjoying a recent period of exuberant ascent, remains, I posit, in the nascent stages of a truly spectacular unfolding. The macrocosm, you see, continues to favor the VanEck Semiconductor ETF (SMH 2.58%). A rather pedestrian name for a vehicle poised to carry one towards potentially above-average returns, but then, subtlety is rarely a virtue of the ticker symbol.